February 02, 2009
Lead counsel for the plaintiffs in a securities class action alleging that Forest Laboratories Inc. provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro have asked for more than $18 million in fees and expenses.
December 29, 2008
A judge has given preliminary approval to a $65 million settlement that allows Forest Laboratories to end a securities class action that claimed it provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro.
November 11, 2008
Forest Laboratories Inc. has reached a tentative settlement of $65 million in a securities class action that claimed the company provided misleading information about the safety of its blockbuster antidepressants, Celexa and Lexapro.
October 29, 2007
A judge in the multidistrict securities litigation against Forest Laboratories Inc. on Friday granted class status to a group of plaintiffs that say the drug maker provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro.